Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine

Journal of Headache and Pain

Volumn 11, Issue 2, 2010, Pages 151-156

  Gentile, Giovanna ^a   Missori, Serena ^a   Borro, Marina ^a   Sebastianelli, Alisa ^a   Simmaco, Maurizio ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic migraine; Genetic liability; Pharmacogenomics; Pyrosequencing; Triptans

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; GUANINE NUCLEOTIDE BINDING PROTEIN BETA 3 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); CYP1A2 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; G PROTEIN BETA3 SUBUNIT; G-PROTEIN BETA3 SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; TRYPTAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC CODE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSFORMED MIGRAINE; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; CHRONIC DISEASE; DRUG RESISTANCE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MIGRAINE; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC TESTING; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIGRAINE DISORDERS; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; TRYPTAMINES;

EID: 77953387951     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-010-0202-7     Document Type: Article

References (24)

1. Headache Classification Committee, Olesen J, M-G-Bousser, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742-746.
2. Manack A, Turkel C, Silberstein S (2009) The evolution of chronic migraine: classification and nomenclature. Headache 49:1206-1213.
3. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2009) Global prevalence of chronic migraine: a systematic review. Cephalalagia. doi:10.1111/j.1468-2982.2009.01941.x.
4. Ferrari A, Sternieri E, Ferraris E, Bertolini A (2003) Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 48:1-9.
5. Schürks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D (2007) G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 82:396-401.
6. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, Nöthen MM, Maffei P, Franke P, Fritze J, Maier W, Propping P, Beckmann H, Bellodi L, Lesch KP (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 8:621-624.
7. Rodriguez S, Gaunt TR, Day INM (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. doi:10.1093/aje/kwn359.
8. Thibaudin L, Berthoux P, Thibaudin D, Mariat C, Berthoux F (2004) G protein beta3 subunit C825T polymorphism in primary IgA nephropathy. Kidney Int 66:322-328.
9. Garsa AA, McLeod HL, Marsh S (2005) CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 9;6:19.
10. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E (2005) Influence of the genetic polymorphism in the 50-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587:59-66.
11. Filic V, Vladic A, Stefulj J, Cicin-Sain L, Balija M, Sucic Z, Jernej B (2005) Monoamine oxidases A and B gene polymorphisms in migraine patients. J Neurol Sci 228:149-153.
12. Sabol SZ, Hu S, Hamer D (1998) A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103:273-279.
13. Panconesi A (2008) Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 9:267-276.
14. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C?A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
15. Nakajima M, Yokoi T, Mizutani T, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem Tokyo 125:803-808.
16. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 10:209-216.
17. Cornelis MC, El-Sohemy A, Campos H (2004) Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 41:758-762.
18. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5:410-417.
19. Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME (2006) Which triptan for which patient? Neurol Sci 27(Suppl 2):S123-S129.
20. Skarke C, Kirchhof A, Geisslinger G, Lötsch J (2005) Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol 61:887-892.
21. Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9:1267-1269.
22. Asuni C, Cherchi A, Congiu D, Piccardi MP, Del Zompo M, Stochino ME (2007) Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8:185-189.
23. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Inter Emerg Med 4:367-373.
24. Stovner L, Tronvik E, Hagen K (2009) New drugs for migraine. J Headache Pain 10:395-406.